一种新型的 ANG-BSA/BCNU/ICG MNPs 用于胶质母细胞瘤的靶向治疗。
A Novel ANG-BSA/BCNU/ICG MNPs Integrated for Targeting Therapy of Glioblastoma.
机构信息
Department of Radiology, the First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People's Hospital,3002 SunGangXi Road, Shenzhen, China.
The Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510282, People's Republic of China.
出版信息
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241281321. doi: 10.1177/15330338241281321.
PURPOSE
Develop an albumin nanoparticle-based nanoprobe for targeted glioblastoma (GBM) diagnosis and treatment, utilizing Angopep-2 for low-density lipoprotein receptor-related protein (LRP) targeting.
METHODS
Combined albumin-coated superparamagnetic iron oxide (SPIO), Carmustine (BCNU), and indocyanine green (ICG). Assessed morphology, size, Zeta potential, fluorescence, and drug encapsulation. Conducted in vitro fluorescence/MRI imaging and cell viability assays, and in vivo nanoprobe accumulation evaluation in brain tumors.
RESULTS
ANG-BSA/BCNU/ICG MNPs exhibited superior targeting and cytotoxicity against GBM cells in vitro. In vivo, enhanced brain tumor accumulation during imaging was observed.
CONCLUSION
This targeted imaging and drug delivery system holds promise for efficient GBM therapy and intraoperative localization, addressing Blood-brain barrier (BBB) limitations with precise drug delivery and imaging capabilities.
目的
开发一种基于白蛋白纳米颗粒的纳米探针，用于靶向脑胶质瘤（GBM）的诊断和治疗，利用 Angopep-2 进行低密度脂蛋白受体相关蛋白（LRP）靶向。
方法
将载有 Angiopep-2 的白蛋白包覆超顺磁性氧化铁（SPIO）、卡莫司汀（BCNU）和吲哚菁绿（ICG）结合在一起。评估形貌、尺寸、Zeta 电位、荧光和药物包封。进行体外荧光/MRI 成像和细胞活力测定，以及体内脑肿瘤中纳米探针的积累评估。
结果
ANG-BSA/BCNU/ICG MNPs 表现出对体外 GBM 细胞的优异靶向性和细胞毒性。在体内，观察到成像期间增强的脑肿瘤积累。
结论
这种靶向成像和药物传递系统有望实现高效的 GBM 治疗和术中定位，通过精确的药物传递和成像能力解决血脑屏障（BBB）的限制。
Zotero 插件